Fernand Labrie
Publications
Page 7 of 8, showing 50 records out of 368 total, starting on record 301, ending on 350
| Publication | Category | Year |
|---|---|---|
| 348. Labrie, F., Ferland, L., Lagacé, L., Drouin, J., Asselin, J., Azadian-Boulanger, G., Raynaud, J.P. (1977) High inhibitory activity of R5020, a pure progestin, at the hypothalamic-adenohypophyseal level on gonadotropin secretion. Fertil. Steril., 28: 1104-1112. | Prostate Cancer | 1977 |
| 327. Labrie, F., Godbout, M., Bélanger, A., Lefebvre, F.A., Séguin, C., Pelletier, G., Cusan, L., Kelly, P.A., Reeves, J.J. (1981) Mechanisms of the antifertility effects of LHRH agonists in the male rat, in: Shelton, J.D., Zatuchni, G.I. et Sciarra, J.J., eds: LHRH peptides as female and male contraceptives, Philadelphia, Harper & Row, pp 246-260. | Prostate Cancer | 1981 |
| 243. Labrie, F., Luthy, I., Veilleux, R., Simard, J., Bélanger, A., Dupont, A. (1987) New concepts on the androgen sensitivity of prostate cancer, in: Murphy, G.P., Khoury, S., Kuss, R., Chatelain, C. et Denis, L., eds: Progress in Clinical and Biological Research. Prostate cancer Part A: Research. Endocrine treatment and histopathology, pp 145-172. | Prostate Cancer | 1987 |
| 244. Labrie, F., Poulin, R., Simard, J., Hubert, J.F., Spinola, P., Marchetti, B. (1987) Adrenal steroids exert potent estrogen action in both normal and cancer tissue, in: Klijn, J.G.M., Paridaens, R. et Foekens, J.A., eds: Hormonal Manipulation of Cancer: Peptides Growth Factors and New (Anti-) Steroidal Agents. Monograph Series of the European Organization for Research on Treatment of Cancer, New York, Raven Press, pp 7-16. | Prostate Cancer | 1987 |
| 352. Labrie, F., Savary, M., Coy, D.H., Coy, E.J., Schally, A.V. (1976) Inhibition of luteinizing hormone release by analogs of luteinizing hormone-releasing hormone (LHRH) in vitro. Endocrinology, 98: 289-94. | Prostate Cancer | 1976 |
| 68. Labrie, F., Simard, J., Coquet, A., Leblanc, G., Candas, B. (1999) Relative potency of bicalutamide (Casodex) and Flutamide (Eulexin) [Letter to the Editor: Reply by the authors re: 50: 913-919, 1997]. Urology, 54: 195-197. | Prostate Cancer | 1999 |
| 104. Labrie, F., Simard, J., Luu-The, V., Labrie, C., Bélanger, A. (1996) Adrenal androgens are responsible for 40-50% and not 5-10% of total prostatic androgens in 65-year-old men: intracrinology, in First International Consultation on Prostate Cancer, Monaco, pp Published on CD-ROM. | Prostate Cancer | 1996 |
| 296. Labrie, F., Tremblay, Y., Bélanger, A., Dupont, A. (1984) Medical castration is easily achieved with LHRH agonists, in: Scierra, J.J., ed. 5th International Meeting on Fertility Control, Genoa, Italy, pp 49-60. | Prostate Cancer | 1984 |
| 262. Labrie, F., Veilleux, R. (1986) A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate, 8: 293-300. | Prostate Cancer | 1986 |
| 214. Labrie, F., Veilleux, R., Fournier, A. (1988) Low androgen levels induce the development of androgen hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. J. Natl. Cancer Inst., 80: 1138-1147. | Prostate Cancer | 1988 |
| 215. Labrie, F., Veilleux, R., Fournier, A. (1988) Maintenance of androgen responsiveness by glucocorticoids in Shionogi mammary carcinoma cells in culture. J. Natl. Cancer Inst., 80: 966-970. | Prostate Cancer | 1988 |
| 191. Lacoste, D., Caron, S., Bélanger, A., Labrie, F. (1989) Effect of 3-week treatment with [D-Trp6, des-Gly-NH210]LHRH ethylamide, aminoglutethimide, ketoconazole or Flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog. J. Steroid Biochem., 33: 233-242. | Prostate Cancer | 1989 |
| 192. Lacoste, D., Dubé, D., Bélanger, A., Labrie, F. (1989) Effect of 2-week combination therapy with the LHRH agonist [D-Trp6,des-Gly-NH2]LHRH ethylamide and the antiandrogen Flutamide on prostate structure and steroid levels in the dog. Mol. Cell. Endocrinol., 67: 131-138. | Prostate Cancer | 1989 |
| 193. Lacoste, D., Dubé, D., Trudel, C., Bélanger, A., Labrie, F. (1989) Normal gonadal functions and fertility after 23 months of treatment of prepubertal male and female dogs with the GnRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide. J. Androl., 10: 456-465. | Prostate Cancer | 1989 |
| 194. Lacoste, D., Labrie, F., Dubé, D., Bélanger, A., Tice, T., Gilley, R.M., Pledger, K.L. (1989) Reversible inhibition of testicular androgen secretion by 3-, 5- and 6-month controlled-release microsphere formulations of the LHRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide in the dog. J. Steroid Biochem., 33: 1007-1011. | Prostate Cancer | 1989 |
| 216. Lacoste, D., St-Arnaud, R., Bélanger, A., Labrie, F. (1988) A pure antiandrogen does not interfere with the LHRH agonist-induced blockade of testicular androgen secretion in the dog. Mol. Cell. Endocrinol., 56: 141-147. | Prostate Cancer | 1988 |
| 217. Lacoste, D., St-Arnaud, R., Caron, S., Bélanger, A., Labrie, F. (1988) The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole. J. Steroid Biochem., 31: 963-970. | Prostate Cancer | 1988 |
| 263. Lacourcière, Y., Dupont, A., Giguère, M., Labrie, F. (1986) L'utilité de la scintigraphie osseuse dans l'évaluation de l'atteinte squelettique du cancer de la prostate traité à l'aide d'une association LHRH-antiandrogènes. Union Med. Can., 115: 229-234. | Prostate Cancer | 1986 |
| 297. Lefebvre, F.A., Bélanger, A., Pelletier, G., Labrie, F. (1984) Recovery of gonadal functions in the adult male rat following cessation of 5-month daily treatment with an LHRH agonist. J. Androl., 5: 181-192. | Prostate Cancer | 1984 |
| 315. Lefebvre, F.A., Séguin, C., Bélanger, A., Caron, S., Sairam, M.R., Raynaud, J.P., Labrie, F. (1982) Combined long-term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat. Prostate, 3: 569-578. | Prostate Cancer | 1982 |
| 218. Luthy, I., Bégin, D., Labrie, F. (1988) Mediation by the androgen receptor of the stimulatory and antiandrogenic actions of 17?-estradiol on the growth of androgen-sensitive Shionogi mammary carcinoma cells in culture. Endocrinology, 123: 1418-1424. | Prostate Cancer | 1988 |
| 245. Luthy, I., Labrie, F. (1987) Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamide. Prostate, 10: 89-94. | Prostate Cancer | 1987 |
| 219. Luthy, I.A., Bégin, D.J., Labrie, F. (1988) Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J. Steroid Biochem., 31: 845-852. | Prostate Cancer | 1988 |
| 4699. Ma, C., Yoshioka, M., Boivin, A., Gan, L, Takase, Y, Labrie, F., St-Amand, J. (2009) Atlas of dihydrotestosterone actions on the transcriptome of prostate in vivo. The Prostate, 69: 293-316 | Prostate Cancer | 2009 |
| 298. Marchetti, B., Labrie, F. (1984) Further characterization of the direct inhibitory effect of LHRH agonists at the testicular level in the rat. J. Steroid Biochem., 20: 339-342. | Prostate Cancer | 1984 |
| 220. Marchetti, B., Labrie, F. (1988) Characteristics of Flutamide action on prostatic and testicular functions in the rat. J. Steroid Biochem., 29: 691-698. | Prostate Cancer | 1988 |
| 221. Marchetti, B., Poulin, R., Plante, M., Labrie, F. (1988) Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostate. J. Steroid Biochem., 31: 411-419. | Prostate Cancer | 1988 |
| 195. Monfette, G., Dupont, A., Labrie, F. (1989) Temporary combination therapy with Flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 41-42. | Prostate Cancer | 1989 |
| 196. Monfette, G., Dupont, A., Pinault, S., Gagnon, J., Boivin, J.C., Têtu, B., Labrie, F. (1989) Advantages of downstaging local prostate cancer by 3-month combination therapy prior to radical prostatectomy, in Fourth International Symposium on Transrectal Ultrasound in the Diagnosis and Management of Prostate Cancer, New York, Alan R. Liss Inc., pp 255-261. | Prostate Cancer | 1989 |
| 246. Moorjani, S., Dupont, A., Labrie, F., Lupien, P.J., Brun, D., Gagné, C., Giguère, M., Bélanger, A. (1987) Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostate cancer. Metabolism, 36: 244-250. | Prostate Cancer | 1987 |
| 222. Moorjani, S., Dupont, A., Labrie, F., Lupien, P.J., Gagné, C., Brun, D., Giguère, M., Bélanger, A., Cusan, L. (1988) Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen and combination treatment with LHRH agonist and Flutamide. J. Clin. Endocrinol. Metab., 66: 314-322. | Prostate Cancer | 1988 |
| 345. Pelletier, G., Cusan, L., Auclair, C., Kelly, P.A., Désy, L., Labrie, F. (1978) Inhibition of spermatogenesis in the rat by treatment with [D-Ala6, des-Gly-NH210]LHRH ethylamide. Endocrinology, 103: 641-643. | Prostate Cancer | 1978 |
| 337. Pelletier, G., Cusan, L., Bélanger, A., Séguin, C., Kelly, P.A., Labrie, F. (1980) Further studies on the inhibitory effects of [D-Ala6, des-Gly-NH210]LHRH ethylamide on spermatogenesis and steroidogenesis in the rat: Reversibility and effect of androgen administration. J. Androl., 1: 171-181. | Prostate Cancer | 1980 |
| 223. Pelletier, G., Labrie, C., Simard, J., Duval, M., Martinoli, M.G., Zhao, H., Labrie, F. (1988) Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in situ hybridization. J. Mol. Endocrinol., 1: 213-223. | Prostate Cancer | 1988 |
| 78. Pelletier, G., Luu-The, V., Huang, X.F., Lapointe, H., Labrie, F. (1998) Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin. J. Urol., 160: 577-582. | Prostate Cancer | 1998 |
| 4726. Pelletier, G., Luu-The, V., Tetu, B., Labrie, F. (1999) Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem Cytochem., 47: 731-738. | Prostate Cancer | 1999 |
| 277. Perez, C.A., Fair, W.R., Ihde, D.C., Labrie, F. (1985) Cancer of the prostate, in: De Vita, V.T., Hellman, S. et Rosenberg, C., eds: Cancer: Principles and Practice of Oncology, Philadelphia, J.P. Lippincott, pp 929-964. | Prostate Cancer | 1985 |
| 197. Pinault, S., Gagnon, J., Monfette, G., Têtu, B., Dupont, A., Labrie, F. (1989) Transrectal ultrasound evaluation of local disease in prostate cancer patients treated with the combination therapy, in: Labrie, F., Lee, F. et Dupont, A., eds: Early State Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 53-62. | Prostate Cancer | 1989 |
| 224. Plante, M., Lapointe, S., Labrie, F. (1988) Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. J. Steroid Biochem., 31: 61-64. | Prostate Cancer | 1988 |
| 264. Poyet, P., Gagné, B., Labrie, F. (1986) Characteristics of the ?-adrenergic stimulation of adenylate cyclase activity in rat ventral prostate and its modulation by androgens. Prostate, 9: 237-245. | Prostate Cancer | 1986 |
| 265. Poyet, P., Gagné, B., Lavoie, M., Labrie, F. (1986) Characteristics of the ?-adrenergic receptor in the rat ventral prostate using [125I]cyanopindolol. Mol. Cell. Endocrinol., 48: 59-67. | Prostate Cancer | 1986 |
| 278. Poyet, P., Labrie, F. (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol. Cell. Endocrinol., 42: 283-288. | Prostate Cancer | 1985 |
| 341. Raynaud, J.P., Bonne, C., Bouton, M.M., Lagacé, L., Labrie, F. (1979) Action of a non -steroidal anti -androgen, RU23908, in peripheral and central tissues. J. Steroid Biochem., 11: 93-99. | Prostate Cancer | 1979 |
| 299. Raynaud, J.P., Bonne, C., Moguilewsky, M., Lefebvre, F.A., Bélanger, A., Labrie, F. (1984) The pure antiandrogen, RU23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review. Prostate, 5: 299-311. | Prostate Cancer | 1984 |
| 266. Raynaud, J.P., Coussedière, D., Moguilewsky, M., Pottier, J., Labrie, F. (1986) Cancer de la prostate: bases biologiques pour l'emploi d'un antiandrogène dans le traitement. Bulletin du Cancer, 73: 36-46. | Prostate Cancer | 1986 |
| 279. Raynaud, J.P., Moguilewsky, M., Tournemine, C., Pottier, J., Coussedière, D., Salmon, J., Husson, J.M., Bertagna, C., Tremblay, D., Pendyala, L., Brisset, J.M., Vallancien, G., Serment, G., Navratil, N., Dupont, A., Labrie, F. (1985) Pharmacology and clinical studies with RU23908 (Anandron). EORTC Genitourinary Group Monograph 2, Part A, in: Schroeder, F.H. et Richards, B., eds: Therapeutic Principles Metastatic Protastic Cancer, New York, Alan R. Liss Inc., pp 99-120. | Prostate Cancer | 1985 |
| 316. Resko, J., Bélanger, A., Labrie, F. (1982) Effects of chronic treatment with a potent LHRH agonist on serum LH and steroid levels in the male rhesus monkey. Biol. Reprod., 26: 378-384. | Prostate Cancer | 1982 |
| 226. Rousseau, L., Dupont, A., Labrie, F., Couture, M. (1988) Sexuality and antihormonal therapy in prostate cancer, in: Eicher, W. et Kockott, G., eds: Sexology, Berlin, Springer-Verlag, pp 290-303. | Prostate Cancer | 1988 |
| 225. Rousseau, L., Dupont, A., Labrie, F., Couture, M. (1988) Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen Flutamide with medical (LHRH agonist) or surgical castration. Arch. Sex. Behav., 17: 87-98. | Prostate Cancer | 1988 |
| 4723. Samson, M., Labrie, F., Luu-The, V. (2010) Sequential transformation of 4-androstenedione into dihydrotestosterone in prostate carcinoma (DU-145) cells indicates that 4-androstenedione and not testosterone is the substrate of 5alpha-reductase. Horm Mol Clin Invest. 1: 67-72. | Prostate Cancer | 2010 |